GlassScriptPhysician profile
Jonathan William Prokop
NPI 1124541461
$2,297.71
in general payments reported to CMS, 2019-2025
16 companies · $95.82 in 2025
The $95.82 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $1,390 · 2023: $242 · 2024: $87.41 · 2025: $95.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $446.67 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.82 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $314.13 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $242.03 | 2021-2023 | Spravato |
| Lundbeck LLC | $183.50 | 2021-2023 | Rexulti |
| Abbvie INC. | $157.32 | 2021-2023 | |
| Corium, LLC | $139.31 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $132.74 | 2023-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $93.09 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $72.12 | 2022 | |
| Neos Therapeutics, LP | $53.67 | 2022-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $50.37 | 2022 | |
| Avanir Pharmaceuticals, INC. | $25.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.84 | 2025 | Qelbree |
| Biogen, INC. | $21.69 | 2025 | Zurzuvae |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Prokop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.